Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
NCT ID: NCT01478191
Last Updated: 2013-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
495 participants
OBSERVATIONAL
2010-05-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. B symptoms(yes/no)
2. relapse in previously irradiated areas(yes/no)
3. Ann Arbor Stage (III/IV vs I/II)
4. disease status at accrual (refractory vs relapsed)
5. Early relapse within 12 months of Complete Response (CR) versus late relapse after Complete Response (CR) lasting \> l2 months",
6. extranodal involvement (yes/no).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04419441
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
NCT00636311
IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
NCT01333605
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
NCT01884428
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
NCT05595447
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years
* Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR.
Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion).
* Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up
* Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen.
* First IGEV course started before December 31st 2007
* Assessment of tumor response by Cheson 1999 criteria 11
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Italiana Linfomi - ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Armando Santoro, Prof.
Role: PRINCIPAL_INVESTIGATOR
Istituto Clinico Humanitas
Monica Balzarotti, Dr.
Role: PRINCIPAL_INVESTIGATOR
Istituto Clinico Humanitas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Oncologico del Mediterraneo
Catania, Catania, Italy
Policlinico Maggiore
Milan, Italy, Italy
Ospedale San Gennaro
Napoli, Italy, Italy
Azienda Ospedaliera V. Cervello
Palermo, Italy, Italy
Azienda Ospedaliera "Bianchi Melacrino Morelli"
Reggio Calabria, Italy, Italy
Presidio Ospedaliero - Unità Complessa Ematologia
Treviso, Italy, Italy
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
Milan, Milano, Italy
SCDU Ematologia, AOU Maggiore della Carità
Novara, Novara, Italy
Ospedale dell'Angelo
Mestre, VE, Italy
A.O.SS. Biagio, Antonio e Cesare Arrigo
Alessandria, , Italy
AORN San G.Moscati
Avellino, , Italy
Centro di riferimento Oncologico - Oncologia Medica A
Aviano (PN), , Italy
Divisione di Ematologia Spedali Civili
Brescia, , Italy
Ospedale di Circolo
Busto Arsizio - VA, , Italy
Divisione di Ematologia Osp.Businco
Cagliari, , Italy
Ospedale civile Divisione di Ematologia
Civitanova Marche (MC), , Italy
Ospedale S Martino
Genova, , Italy
Ospedale San Martino - Divisione di Ematologia
Genova, , Italy
Ospedale Santa Maria Goretti
Latina, , Italy
A O Papardo
Messina, , Italy
Azienda Ospedaliero Universitaria Policlinico Gaetano Martino
Messina, , Italy
Osp. San Carlo Borromeo Divisione di Oncologia Medica
Milan, , Italy
Ospedale Niguarda CA' Granda
Milan, , Italy
Policlinico di Modena - Università degli studi
Modena, , Italy
AOU Federico II di Napoli
Napoli, , Italy
Ospedale Umberto I UO Med. Interna Oncoematologia
Nocera Inferiore (SA), , Italy
A.O. di Padova Divisione di Oncologia Medica
Padua, , Italy
Policlinico P.Giaccone
Palermo, , Italy
Fondazione Policlinico San Matteo
Pavia, , Italy
Ospedale Santo Spirito Dipartimento di Ematologia
Pescara, , Italy
Ospedale Civile G.da Saliceto - UOA Ematologia
Piacenza, , Italy
AO Santa Maria Nuova
Reggio Emilia, , Italy
Ospedale Oncologico regionale CROB
Rionero in Vulture (PZ), , Italy
Ospedale S. Eugenio
Roma, , Italy
Policlinico Università Tor Vergata
Roma, , Italy
Univeristà La Sapienza
Roma, , Italy
Clinica Humanitas
Rozzano (MI), , Italy
IRCCS Casa Sollievo della Sofferenza
San Giovanni Rotondo (FG), , Italy
Istituto di Ematologia Università degli studi di Sassari
Sassari, , Italy
Ematologia II OspedaleSan Giovanni Battista Molinette
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
30
Identifier Type: OTHER
Identifier Source: secondary_id
IIL-ProHLRec
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.